atepeq/tico19 huggingface dataset:
about how long have these symptoms been going on?
Ye nïïn kä de ca kek nök ke yï la guop kïït e tuany kënë?
and all chest pain should be treated this way especially with your age
ku arɛm puou eben alëu bë tom këlä e rïn ruonku
and along with a fever
ku kek juäi
and also needs to be checked your cholesterol blood pressure
ku riɛmdu awïc bï tïŋ lɔn cï yen rɔt juak
and are you having a fever now?
ku na emën lɔ guop juäi nɛn?
and are you having any of the following symptoms with your chest pain
ku le kït e tuany tɔ̈u kek yïn kek arɛmdu puou
and are you having a runny nose?
ku ye wum lör/wat?
and are you having this chest pain now?
ku rem yï puou emën thiin?
and besides do you have difficulty breathing
ku ye wɛ̈ɛ̈i ïc riɛl ten yïn?
and can you tell me what other symptoms are you having along with this?
ku lëu ba ɣɛn lɛ̈k kïït kök ye kek yök yï guop kek kïït kök kä?
and does this pain move from your chest?
ku ye arɛɛm cath yi puou?
and drink lots of fluids
ku ye dek pïïu juëc
and how high has your fever been
ku cï juäidu rot juak kede
and i have a cough too
ku ɣɛn e ɣɔl aya
and i have a little cold and a cough
ku ɣɛn alir guop ku ɣɛn e ɣɔl aya
and i'm really having some bad chest pain today
ku ɣɛn ala arɛm puou dit tet yakol
and is this the right time for your hay fever
ku e yen kam ye juäi yïn dom ken
and it get the chest pain
ku acï arɛm puou yɔ̈k
and i think i have a little bit of a fever
ku aya tak lɔn le ɣɛn guop juäi thiin nyɔt
and i want you to describe where the chest pain is
ku awiëc ku ba lɛ̈k ɣɛn yen te ye rem yï puou
and she is sorta have the same symptoms
ku yen ala guop kïït tuany töŋkä
and tell me what symptoms are you having now?
ku lɛ̈k ɣɛn ye kïït tuany ko kek tɔ̈u kek yïn emën?
and they're having some fevers as well
ku kek aala gup juäi aya
and with your history of diabetes
ku rin cï yïn guop kaŋ la thukari
and you know it feels like my chest is like gonna crush
ɣɛn a puou yök ciɛ̈t ɣa bi puou guɔ rɔ̈ɔ̈m
and you know people cough on me all the time
ku aŋic lɔn ye kɔc ɣɔl a guop kamthok ebën
and you're having chest pain
ku yïn ala arɛm puou
and your symptoms do not go away in five days
ku kïït e tuany kä aace jäl nïïn kädhïc ïïc
and you said this is a pressure in your chest
ku aye luel ken kene e yi nyiɛc puou
anyone in the family have a heart problem heart disease heart attack high cholesterol high blood pressure
kuat ran eben macthok ala ke jɔ̈ɔ̈r puou ic tuɛny puou, ke jɔ̈ɔ̈r puou ic, ku thukari e riɛmic
any other symptoms or problems that you notice with the muscle aches?
le kïït tuany kök wula kä jɔ̈ɔ̈r ye yɔ̈k rïŋ ic?
any sharp pain on your left side of your chest?
le arɛm moth thok ye yök alɔŋ puon camic?
are there other people sick as you at home with your same symptoms?
le kɔc kök tuany cïmen du bai ku aala kïït töŋkä?
are you having any difficulty breathing now
ku ye wɛ̈ɛ̈i ic riɛl tën yïn emën
are you having any other symptoms?
ku le kïït kök e tuany tɔ̈u kek yïn?
are you having any shortness of breath?
ku ye wɛ̈i tɛmm tën yïn?
are you still having the chest pain
ŋuɔ̈t yï rem puou emën
because this is flu season
rin kamken e kam juäi
besides the diabetes do you have other problems or important diseases?
cïmen thukari le ke dɛ̈t jɔ̈ɔ̈r wula tuɛnytuɛny riil tou kek yin?
but also we shouldn't be put aside for the heart cardiac origin chest pain
ku ok aacï lëu bï ok puoc thook rin tuany puou
but a more important problem now is this chest pain
ku ke ril apɛi emën e arɛm puou kën
but if you have the cough
ku na ye ɣɔl
but i have difficulty breathing
ku wɛ̈ɛ̈i e ic riɛl ten ɣɛn
but i know lot of people cough on me
ku aŋic lɔn ye kɔc juëc ɣɔl a guop
but we need to treat every chest pain with the utmost seriousness
ku awïcku ku bï tuɛny puou ya dem apath
but you're breathing all right right now right?
ku na mën ye ŋiɛ̈c wɛ̈ɛ̈i?
cause of this chest pain i totally forgot
ku rin arɛm puou ken ɣɛn e nhom guo määr
cause they're having a cough
rin kek aala ɣɔl
does it feel like somebody squeezing your chest
ye ciɛ̈t ke la raan yi nyiɛc puou
do still feel like shortness of breath
aŋuöt ya yök ke wɛ̈ɛ̈i ye ic riɛl.
do they complain of being sick similar symptoms?
ye kä yök ciɛ̈t ke la gup kïït e tuany töŋ kën?
do you have any blood pressure problem as far as you know?
ciɛ̈t yï la guop dakät tecït te ŋiɛ̈c yen?
do you have any other chronic like high blood pressure or anything like that?
ciɛ̈t yï la guop tuany cïmen dakät wula kuat tuanydɛ̈t?
do you have any other diseases chronic medical problems like diabetes?
ciɛ̈t yï la guop tuany e wal cïmen thukari?
do you have any shortness of breath with that chest pain?
ciɛ̈t wɛ̈ɛ̈i ye ic riɛl ten yïn kek arɛm puou?
do you have high blood pressure?
lɔ guop dakät?
do you have some shortness of breath goes with that?
ciɛ̈t wɛ̈ɛ̈i e ic riɛl e cath kek tuany ëë?
do you know what symptoms she was having?
ciɛ̈t yï ŋic kïït tuany ke tɔ̈u kek yen?
do your relatives have the same symptoms
le ran manydu thok la guop kïït e tuany kä
do you see the image?
ciɛ̈t ye kït tïŋ?
drink plenty of fluids today
dek pïïu juëc yaköl
have a dry cough a cold and runny nose vomiting diarrhea
ala ɣɔl aliɛr guop ku lɔ̈r wum aŋɔ̈k ku yɛ̈c
however i take tests for the diabetes
ku ɣɛn acï them guop thukari
however she has symptoms quite similar to mine
ku yen ala guop kïït e tuany thöŋ kek käkie
how high is your fever?
juäidu cï rɔt juak kede?
how' s your blood pressure?
ku na dakätdu yïnde?
i don't think i have high blood pressure
acä ye tak lɔn le ɣɛn gup dakät
i feel a pain in the chest here in the front part of the chest
arɛm puou aya yök ɣa puou tueŋ tën
if you continue to have high fevers
ku na ŋuɔ̈t yï la guop juai
if you have a fever of a hundred and two or higher
ku na cï juandu rɔt juak ku bi ya buɔt ku rɔu wula ke la nhial
if you think that your symptoms or problems warrant a better look
ku na ya yök lɔn ka kïït e tuany wula ka kök jɔ̈ɔ̈ aala lɛ̈u bï kek tïŋ
i got a fever yesterday
juäi adom ɣɛn wäraköl
i got a slight fever too
ku ɣɛn ala guop juanthiin kɔr
i had a fever yesterday
ɣɛn ala guop juäi wäraköl
i had a short sharp pain in my chest
ɣɛn ala arɛm moth thok ɣa puou
i have a sharp pain here in the chest
arɛm moth thok atɔ̈u ɣa puou
i have hay fever though too
ɣɛn ala juäi aya
i have made on the body around the chest area?
ɣɛn ala arɛm guop ku alɔŋ puou?
i have some difficulty breathing too
wɛ̈ɛ̈i e ic riɛl ten ɣɛn aya
i'll send you an image
yïn aba tuɔ̈c e kït
i'm having some chest pain today
ɣɛn ala arɛm puou yakol
i'm just having some headaches and some fever today
ɣɛn aɣar nhom ku juäi yakol
in my opinion it is flu
tecït ta ya tak yen e juäi
in my opinion this is a little flu
tecït ta ya tak yen kën e juanthiin kɔr
i see it going from the center of your chest going up to your neck
aya tïŋ ke jäl yï puou ku ala yï yeth
is it like some heavy heavy person sitting on your chest?
ye ciɛ̈t ke cï ran thiek apɛi nyuoc puou?
it all started with the headaches and with the fever about the same time
acï jok aɣar nhom ku jɔl a juäi kamtöŋ kën
it hurts in the chest
puou aye rem apɛi
it hurts in the middle of my chest
ye ɣɛn rem puou ciɛlic
it is a pressure like chest pain
ye kedït cït arɛm puou
it is in my chest
atɔ̈u ɣa puou
it is in the center of my chest
atɔ̈u ɣa pɛm ciɛlic
it is in the center of the chest
atɔ̈y ɣa puou ciɛlic
it is occurring right in the middle of my chest
e rɔt loi ɣa puou ciɛlic
it is right in the center of my chest
atɔ̈u ɣa pɛm ciɛlic
it sounds like you just may have the garden variety cold or a flu
yïn aciɛ̈t kela kuat aliɛ ku juäi
i've got pain in my chest
ɣɛn arem puou
i've very concerned of this chest pain
ɣɛn adiɛr arɛm puou kën
i want you to tell me in describing this chest pain
lɛ̈k ɣɛn te rem yï puou thïn
i will send you an image
yïn aba tuɔ̈c kit
i will send you an image on your screen
yïn aba tuɔ̈c kït wɛ̈nhdu nyin
like high blood pressure or diabetes
cïmen dakät wula thukari
like right in the center of the chest
cïmen cuɛ̈c e puou ciɛlic
most of the time it is this type of chest pain
e yen kuat arɛm puou kamthok ebën
my sister has similar symptoms
nyankäi ala kïït e tuany kën aya
now for the fever you can take a tachipirina sweet
e rin juäi yïn alɛ̈u ku ba tachipirina diny dek
now i send you an image
yïn atuɔ̈c kït emën
now mary how many days have you had the symptoms
mary ye nïïn käde kek ca nök kek kïït e tuany kä
now you said you have a chest pain
aca luel emën lɔn le yïn arɛm puou
occasionally i have some chest pain
aköl kök ɣɛn anaŋ arɛm puou
okay are you having any other symptoms along with this other than just the pain
apath le kuat kïït tuany kök tɔ̈u kek kën pɛ̈l arɛm
or if you have high blood pressure
wula te le yïn dakät
or somebody sitting on your chest?
wula ciɛt le ran cï nyuc yï puou?
pretty much the same with the fever and the cough headache and muscle pains
ku a thɔ̈ɔ̈ŋ kek juäi/atuöc ku ɣɔl arɛm nhom ku arɛm rïŋ ic
right in the middle of my chest
ɣa puou ciiɛlic
show me on this image where you feel the pain
nyuɔ̈th ɣɛn e kïn kënic te ye yïn arɛm yök thïn
since you have a fever
rin le yïn juäi
so do you think that some of these symptoms could be related to being pregnant?
ye yök ka kïït kä aa kïït ye nyuɔth lɔn liɛc yïn?
so your chest pain started this morning
arɛm puou ajök mënnhiääk
so your children are having some of the same symptoms?
ku na miɛ̈thku lek gup kïït tuany tööŋ kën aya?
tell me about your chest pain
lɛ̈k ɣɛn arɛmdun puou
the fever increases at night
juäi e rɔt juak wakɔ̈u
the fever i've had for the last two days
juäi kën atɔ̈u kek ɣɔn tecït tën nïïn karɔu
the fever started to increase last night
juäi ajɔl rɔt juak wärthɛ̈i
the fever started two days ago
juäi ajɔ̈k tecït tën nïïn karɔu cï jal
the muscle pains with the hay fever
rïŋ arem ic kek juäi
this is doctor porter in the emergency room triage center
kënë e akim cɔl porter tɔ̈u alɔŋ ɣɔ̈n ye kɔc tïŋ gup thïïn
well can you tell me a little bit more about your chest pain?
apath cï lɛ̈u bu ba ɣɛn lɛ̈k anyikɔ̈l arɛm piandu?
well from my point of view it is a little flu
apath tecït te ya täk yen ken e juänthiin kɔr
well i feel a pain in the front of my body here in my chest
apath ɣɛn arɛm yök ɣa puou tueŋ
well i've been having a strong pain in my chest
apath ɣɛn ala arɛm dittet ɣa puou
well madam from listening to your symptoms it sounds like you've got one of the flu viruses
apath ma tecït te cï ɣɛn yï piɛŋ thïn yïn ciɛ̈t ka cï luaŋ juäi kom toŋ
well when i have that pain in my chest
apath te le ɣɛn arɛm kën ɣa puou
what kinda pain do you have in your chest?
ye arɛm yïnde yen tɔ̈u yï puou?
when this chest pain started?
ye nɛn yen jɔ̈k arɛm puou kën?
where do you have the pain in the chest?
ye teno yen ye rɛm yï puou?
where you feel this chest pain eel this chest t
te ye rem arɛm puou kënë
you are probably having chest pain
yïn adhil la arɛm puou
you feel like tightness on your chest
yïn rɔt yök ke cï duut puou
you know i got diabetes and stuff
aŋic lɔn le ɣɛn thukari ku jɔl aa kä kök
you said you're having this chest pain
aca luel lɔn yïn arɛm puou
Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020
ken ye nyuoth lɔn ye yen tuany e cɔl coronavirus (COVID-19) pan ɣurupa/pan kɔc ajiɛk pan ɣurupa ku United Kingdom, aköl nïïn1, pɛi tök le aköl 15 pɛi Diak 2020
The cumulative incidence of coronavirus disease (COVID-19) cases is showing similar trends in European Union/European Economic Area countries and the United Kingdom confirming that, while at a different stage depending on the country, the COVID-19 pandemic is progressing rapidly in all countries.
Adat cï matic tuany cɔl coronavirus (COVID-19) e kuat kïït cït käkä nyuɔth pan ɣurupa/kɔc ajiɛk ku United Kingdom acï luel lɔn, ku ke tɔ̈u tëdɛ̈t tëcït ye baai yen tak thïn, tuany COVID-19 ajuak rot gɛɛth ïïc ebën.
Based on the experience from Italy, countries, hospitals and intensive care units should increase their preparedness for a surge of patients with COVID-19 who will require healthcare, and in particular intensive care.
Tecït te cï yen yɔ̈k thïn pan Italy, gɛɛthdit, bɛi akïïm ku te ye kɔc täc thïn aa dhil rɔt guir ku bïk kɔc tuany COVID-19 kony.
On 31 December 2019, a cluster of pneumonia cases of unknown aetiology was reported in Wuhan, Hubei Province, China.
Aköl 31 pɛi Thiärkurɔu 2019, anaŋ tuany puou cï cal pan Wuhan, gendit Hubei pan China.
On 9 January 2020, the China Center for Disease Control and Prevention reported the causative agent as being a novel coronavirus now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Akol nïïn 9 ruon 2020, te ye tuɛnytuɛny muk nhïïm ku gɛ̈l kek acï cal lɔn le ye tuany cɔl coronavirus 2 (SARS-CoV-2) cï tuöl.
Since, the illness resulting from SARS-CoV-2 infection has been named coronavirus disease (COVID-19).
Ku rin cï yen yök lɔn bï yen bei e tuany cɔl SARS-CoV-2 go cäk ke cɔl coronavirɛth (COVID-19).
Evidence to date is that ca 80% of individuals with COVID-19 have a mild disease, i.e. a respiratory tract infection with or without pneumonia, and most of these recover.
Kïït cï yök ke ye tuany nyuɔth 80% la tuany cɔl COVID-19 aala tuɛny puou ye rɔt jɔk wɛ̈ɛ̈i ic, ku e cïmen tuany wɛ̈ɛ̈i ïïc kek wula ke cïn pneumonia, ku kuat käk ye cɔl aŋuɛ̈n.
In ca 14% cases, COVID-19 develops into a more severe disease requiring hospitalisation while the remaining 6% cases experience critical illness requiring intensive care.
14% alɔŋ kɔc cï luaŋ, COVID-19 e cil ku bï ya tuany wïc ran ku bï tääc ku abaŋ tɔ̈u 6% aa kä rɛɛr thïn.
The mortality of patients hospitalised due to COVID-19 is ca 4%.
Kɔc thou panakim cï kek tääc e tuany cɔl COVID-19 e 4%.
In this study, we assess the trends in the cumulative incidence of COVID-19 in each European Union/European Economic Area (EU/EEA) country and the United Kingdom (UK) and compare them to that of Hubei Province, China.
Athɔ̈r kënic, e te cɛɛth cɔl COVID-19 thïn pan Ɣurup/kɔc aa jiɛk pan Ɣurup (EU/EEA) yen acuk them ku buk cath ku acï United Kingdom (UK) thɔ̈ɔ̈ŋ kek pan Hubei, China.
We also compare the current number of COVID-19 cases in EU/EEA countries and the UK with that in Italy during 31 January–15 March 2020.
Ok aacï nimra kɔc tuany COVID-19 bɛ̈ɛ̈i Ɣurup ku UK/EEA thɔ̈ɔ̈ŋ kek nimra kɔc tuany pan Italy aköl nïïn 31 pɛi Tök ɣɛt aköl nïïn 15 pɛi Diäk ruon 2020.
COVID-19 cases in EU/EEA countries and the UK
Kɔc tuany kek COVID-19 bɛ̈ɛ̈i EU/EEA ic ku jɔl a UK
Subsequent to China, COVID-19 underwent further geographical spread and the dynamic of the COVID-19 pandemic in the rest of the world currently follows that of this country.
Cïmen pan China, COVID-19 acï rɔt tɛk piny ku kuat te ye COVID-19 gɛ̈l thïn yen aye buɔthic pinynhom.
On 11 March 2020, the Director General of the World Health Organization (WHO) declared COVID-19 a pandemic.
Aköl 11 pɛi Diäk 2020, bɛ̈ny muk Manadham käk pial Guop pinynhom (WHO) acï COVID-19 cal aɣɛr.
In the 5 March issue of Eurosurveillance 2020, Spiteri et al. reported on the first European confirmed COVID-19 cases according to the WHO case definition.
Te ye wɛ̈l cal thïn alɔŋ käk pial guop pan Ɣurup 2020 aköl 5 pɛi Diäk ,ye cɔl Spiteri et al, ran töŋ tueŋ la guop COVID-19 aci cal WHO
In the EU/EEA, the first three confirmed cases were reported by France on 24 January 2020 in persons returning from Wuhan, Hubei Province, China.
Bɛ̈ɛ̈i EU/EEA ic, kɔc tuany tueŋ kä diäk e France yen ci; kek yɔ̈k thïïn aköl nïïn 24 pɛi Tök ruon 2020 ke ye kɔc ke dhuk ciɛ̈n pan Wuhan, gendit Hubei, China
As at 15 March 2020, COVID-19 cases had been detected in all 30 EU/EEA countries and the United Kingdom (UK), whereby between 31 December 2019 and that date included, 39,768 cases and 1,727 deaths had been reported, with 17,750 cases and 1,441 deaths from Italy alone.
Ku na ye aköl nïïn 15 pɛi Diäk 2020, go COVID-19 yɔ̈k bai 30 ic gɛɛth EU/EEA ku United Kiingdom (UK), ku kam pɛi Thiärkurɔu aköl nïïn 31 ruon 2019 agut yaköl, ran 39,768 acï luaŋ, ran 1,727 aacï thou ku ran 17,750 aacï luaŋ ku ran 1,441 aacï thou pan Italy ye tok path.
Obtaining cumulative number and cumulative incidence of COVID-19 cases
yɔ̈kyɔ̈k nimra kɔc cï luaŋ ku käk cï rɔt loi rin COVID-19
At the European Centre for Disease Prevention and Control (ECDC), the notified COVID-19 case counts in each country worldwide, obtained from only official sources such as the countries’ Ministry of Health, national and regional health authorities and the WHO, are updated each day at 8:00 a.m.
Te ye tuɛnytuɛny tïŋ thïn ku gɛ̈l kek (ECDC), kuat kɔc cï kek yɔ̈k kela gup tuany COVID-19 cï kek yɔ̈k tën kɔc ŋic luɔide aaye wadhara käk pial e bai ku WHO cal thai 8:00 thok ebën ariɛlic.
These data were used for assessing the trends of COVID-19 in EU/EEA and the UK, and comparing them to that in Italy.
Wɛ̈l cï kek yɔ̈k aacï kek luɔ̈i ku bï ke COVID-19 cath bɛ̈ɛ̈i EU/EEA ic ku jɔl a UK, ku jɔl kek thɔ̈ɔ̈ŋ kek Italy.
As a proxy of the prevalence of active COVID-19 cases, we calculated the 14-day truncated cumulative incidence of COVID-19 cases, thus taking into account the natural course of COVID-19, in each EU/EEA country and the UK, during the 1 January–15 March 2020 period.
Tecït te ye COVID-19 rɔt juakk thïn, ok aacï nïïn 14 matic kek käk cï rɔl loi e tuany COVID-19, ku buk ŋic yen kën cɔl COVID-19 abɔ nhiall, kuat pan EU/EEA ku jɔl a UK gɔl cɔ̈k pɛi tök aköl nïïn 15 le pɛi Diäk ruon 2020.
We also presented the cumulative number of notified cases of each country as at 15 March 2020 8:00 a.m. compared with that of Italy for the 31 January–15 March 2020 period.
Ok aacï nimra kuat bai gam gɔl aköl nïïn 15 pɛi Diäk 2020 thäu 8:00 a.m. ku aa cuk thɔ̈ɔ̈ŋ kek nimra pan Italy kën pɛi Tök aköl nïïn 31 le aköl nïïn 15 pɛi Diak 2020.
Trends of COVID-19 in EU/EEA countries and the UK
Kën cäth COVID-19 nyuɔth bɛ̈ɛ̈i EU/EEA ku jɔl a UK
The trends in the 14-day truncated cumulative incidence of COVID-19 cases in EU/EEA countries and the UK generally followed that of Hubei Province (China) (Figure 1).
Cath COVID-19 nïïn 14 bɛ̈ɛ̈i EU/EEA ku jɔl a UK aa cath tök kek kën gen Hubei (China) (thura 1).
For the EU/EEA and the UK overall, the cumulative incidence of COVID-19 started to increase around 21 February and then increased sharply around 28 February 2020 (Supplementary material).
Adat kɔc tuany COVID-19 bɛ̈ɛ̈i EU/EEA ku jɔl UK ecï jɔk bï rot juak tecït tën aköl 21 pɛi Rɔu ku jɔl rɔt juak apɛi pɛi Rɔu aköl nïïn 28 2020 (Athɔ̈r dɛ̈t yen ce luel).
This was mostly driven by the rapid increase in the number of reported cases from Italy, but all other EU/EEA countries and the UK showed similar increasing trends of the cumulative incidence of COVID-19 (Supplementary material).
Adat cï cal gen Italy yen cɔl yen ajuakk rɔt, ku bɛ̈ɛ̈i EU/EEA ku UK aa ke tööŋ kën nyuɔth ke ye te cï COVID-19 rɔt juak thïïn (Athɔ̈r dɛ̈t yen ce luel).
Figure 2 shows the cumulative number of COVID-19 cases, in EU/EEA countries and the UK compared with that in Italy for the 31 January–15 March 2020 period.
Thura 2 e juɛ̈kjuɛ̈k rɔt COVID-19 nyuɔth, bɛ̈ɛ̈i EU/EEA ku jɔl a UK ku thɔ̈ɔ̈ŋ kek ke pan Italy aköl nïïn 31 pɛi Tök le pɛi Diäk aköl nïïn 15 ruon 2020
It highlights that, as at 15 March 8:00 a.m., 15 other EU/EEA countries and the UK had already reported a total number of cases comparable to that of Italy just 3 weeks prior or less.
E adat cï yɔ̈k bɛ̈ɛ̈i EU/EEA ku jɔl a UK ic aköl nïïn 15 pɛi Diäk tha;u 8:00 a.m. nyuɔth adat athɔ̈ɔ̈ŋ kek kën Italy wuthbuɔɔ kä 3 ic dhuk piny.
Our results indicate that the number of notified cases of COVID-19 is rapidly increasing in the EU/EEA and the UK.
Ke cuk yɔ̈k aye nyuɔth lɔn ade ka adat COVID-19 ajuak rɔt bɛ̈ɛ̈i EU/EEA ïïc ku jɔl a UK.
The observed trends in the cumulative incidence of COVID-19 suggest that the pandemic is progressing at a comparable speed in all countries.
Adat cuk yɔ̈k ke tuany COVID-19 aye nyuɔth lɔn ade ka tuany a juak rɔt bɛ̈ɛ̈i kök ic aya.
This is despite countries being at different stages, variations in national public health responses, and possibly different case definitions in countries and different protocols for selecting patients that must be tested for confirmation of COVID-19, including catch-up testing.
Cɔk alɔn cï bɛ̈ɛ̈i juëc yen them kek bɛ̈ɛ̈i ken akïïm ku bï tuany gɛ̈l wei ku dhɔ̈l yeke kɔc cï tuany kuany ku bï kek them gup COVID-19, agut athɛ̈m yeke yɔ̈ɔ̈p.
Early March 2020, doctors in the affected regions of Italy described a situation in which ca 10% of patients with COVID-19 required intensive care and media sources reported that hospitals and intensive care units in these regions had already reached their maximum capacity.
Jɔ̈k cɔ̈k pɛi Diäk 2020, aacï akïïm bɛ̈ɛ̈i cï luaŋ e tuany luel lɔn ka 10% kɔc cï tuany COVID-19 aa wïc kuony dïttet ku bï kek ŋiɛc tiɛt gup wei. ku aacï kɔc wɛ̈l cal aɣɛr luel lɔn ade ka bɛ̈ɛ̈i akïm ku te ye kɔc tääc thïn aacï thiäŋ.
Data on admission of COVID-19 cases in a hospital and/or an intensive care unit are currently available at EU/EEA level for only 6% and 1% cases, respectively (data not shown).
Adat kɔc cï luaŋ ku kɔc cï riääk rin COVID-19 panakïm wula te ye kɔc tääc thïn aye athɔ̈r gäät bɛ̈ɛ̈i EU/EEA ic tecït tën 6% ku jɔl a 1% (wɛ̈l aakï nyuɔth).
They should, however, be collected in a systematic fashion to complement current surveillance data that focus on the number of reported cases and the number of deaths.
Apath ku bï kek ŋiɛc kuöt ïïc apath ku ba thɔ̈r cɛɛth emɛ̈n kuɔny cök kën adat kɔc cï luaŋ ku kɔc cï thou nyuɔth ku bi ŋic.
A study performed in 2010–11 showed a large variation in the availability of intensive care and intermediate care beds in Europe, ranging from 29.2 in Germany to 4.2 beds per 100,000 population in Portugal.
Acï yɔp ku acï yɔ̈k ruon 2010-11 lɔn ade ka ɣɔ̈ɔ̈n ye kɔc tääc thïn pan Ɣurup aacï thɔ̈ɔ̈ŋ, e jɔk 29.2 pan Germany le agen 4.2 tën ran 100,000 pan Portugal.
This means that countries may have more or less resources than Italy (12.5 intensive care and intermediate care beds per 100,000 population in 2010–11).
Kën aye nyuɔth lɔn le bɛ̈ɛ̈i kä juëc wula kä lik te thɔ̈ɔ̈ŋ kek pan Italy (te ye agen ye kɔc tääc thïn ya 12.5 ran 100,000 agut kɔc ruon 2010-11).
Modelling scenarios related to healthcare capacity saturation, with estimates for each EU/EEA country and the UK of the prevalence of hospitalised COVID-19 cases associated with a &gt; 90% risk of exceeding intensive care bed capacity, are provided in the sixth update of the ECDC rapid risk assessment on COVID-19.
Ku bï käk pial guop thɔ̈ɔ̈ŋ kek bɛ̈ɛ̈i EU/EEA ku jɔl a UK rin kɔc cï kek tääc COVID-19 aacïk yɔ̈k tecït tën 90% rin cï ke te ye kɔc tääc baric, ku aacï kek nyuɔth alɔŋ dɛ̈tem cɛɛth käk jɔ̈ɔ̈r alɔŋ ECDC gɛ̈l e tuany cɔl COVID-19
Since cases have so far clustered in certain regions in EU/EEA countries and the UK, and hospitals and intensive care units usually serve a defined regional catchment population, information about cases and intensive care beds should preferably be made available at the Nomenclature of territorial units for statistics 2 (NUTS-2) level.
Ku rin cï tuany ɔt juak bɛ̈ɛ̈i EU/EEA ïïc ku jɔl a UK, bɛ̈ɛ̈i akïk ku ɣɔ̈ɔ̈n ye kɔc tääc thïn aa kɔc yeke lɛ̈u aa kek yeke gam, wɛ̈t rin juɛ̈kjuɛ̈k rɔt e tauny ku agen ye kɔc tääc aaye yɔ̈k alɔŋ Nomenclature of teritorial units for statistics 2 (NUTS-2).
The experience from Italy and the current trends in other countries show that the COVID-19 pandemic is progressing rapidly in the EU/EEA and the UK.
Rin ke cï rɔt looi pan Italy ku ke loi rɔt gɛɛth kök ïïc emën aye nyɔuth lɔn juɛk COVID-19 rɔt EU/EEA ku jɔl a UK.
Countries, hospitals and intensive care units should thus prepare themselves for a scenario of sustained community transmission of SARS-CoV-2 and an increase in the number of patients with COVID-19 requiring healthcare, and in particular intensive care, such as the one occurring in the affected regions of Italy.
Gɛɛth, bɛ̈ɛ̈i akïïm ku ɣɔ̈ɔ̈n ye kɔc tääc thïn aa dhil rɔ̈t guir rin juɛk SARS-CoV-2 rɔt ku rin juɛk kɔc cï luaŋ COVID-19 rɔt, ku e ke wïc ɣɔ̈ɔ̈n ye kɔc tääc thïn cïmen ke cï rɔt looi ɣɔ̈ɔ̈n pan Italy.
As pointed out in the recent ECDC rapid risk assessment, a rapid, proactive and comprehensive approach is essential to delay the spread of SARS-COV-2, with a shift from a containment to a mitigation approach, as the anticipated rapid increase in the number of cases may not provide decision makers and hospitals enough time to comprehend, accept and adapt their response accordingly if not implemented ahead of time.
Cïmen wën cï yen nyuɔth ECDC tuɛnytuɛny gɛ̈l, looi dït awïc ku bï tuany SARS-COV-2 rɔt cï wer piny, ku bï kɔc jäl mukmuk nhom ïc ku tïŋ dhɔ̈l bï ke yen nyai, rin ajuɛ̈k rɔt tuany acï kɔc kä loi bï kony ku jɔl aa bɛ̈ɛ̈i akïm ku bï ke lööi kä detic, gam ku nyɛi kä te cï yen guɔ luɔ̈i kamic.
The rapid risk assessment also lists the public health measures to mitigate the impact of the pandemic.
Ke cï cath acï dhɔ̈l lɛ̈u bï kɔc lui alɔŋ pial guop gät piny ku bï ke tuany gɛ̈l.
There is a short window of opportunity during which countries have the possibility to further increase their control efforts to slow down the spread of SARS-CoV-2 and decrease the pressure on healthcare.
Aril ic apɛi tën gɛɛth ku bïk te bï ke tuany SARS-CoV-2 tek ic ku gɛ̈l la yɔ̈k ku kony kɔc lui alɔŋ pial guop.
Failing this, it is likely that the healthcare systems of other EU/EEA countries will face a surge of patients that require intensive care within the coming days or weeks.
Ku na cï kën rɔt loi, ka bɛ̈ɛ̈i akïm gɛɛth EU/EEA aabï kɔc luaŋ thïn apɛi ku e ke wïc bï kɔc ke nhïïm muk thïn apath nïïn wula wudhbuɔ̈ɔ̈ bï bën.
The outbreak of Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has thus far killed over 3,000 people and infected over 80,000 in China and elsewhere in the world, resulting in catastrophe for humans.
Jɔ̈k cɔ̈k coronavirɛth 2019 (COVID-19) cï jɔk ke ye tuɛny puou (SARS) coronavirus 2 (SARS-CoV-2) acï ran 3,000 nɔ̈k ku ran 80,000 pan China ku pinynhom ɣɔ̈ɔ̈n kök aacï luaŋ, ku kën acï riɔ̈c bɛ̈i ten kɔc.
Similar to its homologous virus, SARS-CoV, which caused SARS in thousands of people in 2003, SARS-CoV-2 might also be transmitted from the bats and causes similar symptoms through a similar mechanism.
Cimen köm ye cɔl homologous, SARS-CoV, ecï tuany cɔl SARS bɛ̈i kɔc gup ruon 2003, tuɛny cɔl SARS-CoV-2 alɛ̈u bï jäl alïk gup ku muɔc kɔc gup kïït e tuan y tɔ̈ɔ̈ŋkä e dhɔ̈l tɔ̈ɔ̈ŋkä aya.
However, COVID-19 has lower severity and mortality than SARS but is much more transmissive and affects more elderly individuals than youth and more men than women.
Ku keya, COVID-19 acï rac bï SARS wuɔ̈r ku ace kɔc nɔ̈k cïmen SARS ku ke rac thïn e wɛ̈t ye yen rɔt guɔ tɛk piny ku aa kɔc cï dhiɔp aa kek ye lac dom ten riɛ̈nythii ku jɔl aa rɔ̈ɔ̈r juëc tën diäär.
In response to the rapidly increasing number of publications on the emerging disease, this article attempts to provide a timely and comprehensive review of the swiftly developing research subject.
Ku kë cï dhuk nhom rin gäät cï rot juak alɔŋ tuany puɔc bën, aye athɔ̈rkën awïc bï ke cï kɔc kuen ku ke cï det ic alɔŋ tuany kën nyuɔth ic aɣer.
We will cover the basics about the epidemiology, etiology, virology, diagnosis, treatment, prognosis, and prevention of the disease.
Kä buk kek jam iic e te bï wäl yɔ̈k thïn, tën ajɔ̈k tuany thïn, ku te käm kɔc luaŋ bën nhial thïn, te ye tuany ŋic thïn, elacde, ku ke ye akïm luel ku gɛ̈lgɛ̈l e tuany.
Although many questions still require answers, we hope that this review helps in the understanding and eradication of the threatening disease.
Cɔk alɔn le yen kïït e thiëc wïc bï kek dhuk nhïïm, aayeku dhil tak lɔn ka wɛ̈l kuan thii kä aabï kony ku tuany detic ku tiɛt rɔt wei.
The Spring Festival on January 25, 2020 has become an unprecedented and unforgettable memory to all Chinese who were urged to stay indoors for all the holiday and for many weeks after due to the outbreak of a novel viral disease.
Aköl 25 pɛi Tök, 2020 yan jɔ̈k cɔ̈k ruon pan China ace aköl kɔŋ ke muör nhïïm rin aake cï thiëc ku bïk rɛ̈ɛ̈r ɣɔ̈ɔ̈tic akɔ̈le ku wudhbuɔ̈ɔ̈ kök rin tuany cï tuɔ̈l.
The virus is highly homologous to the coronavirus (CoV) that caused an outbreak of severe acute respiratory syndrome (SARS) in 2003; thus, it was named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020, and the associated disease was named CoV Disease-19 (COVID-19).
Köm kën athɔ̈ɔ̈ŋ kek coronavirɛth (CoV) acï kɔc dom keye tuɛny puou (SARS) 2003; e Mandhama käk pial guop pinynhoom (WHO) yen ace cäk SARS-CoV-2 pɛi rɔu aköl 11, 2020, ku tuany kën acï cäk ke cɔl CoV tuany-19 (COVID-19).
The epidemic started in Wuhan, China, and quickly spread throughout the entire country and to near 50 others all over the world.
Tuany kën e jɔk rɔt gen Wuhan, China ku jɔl rɔt tɛk piny gɛu ic ebën ku jɔl a gɛu 50 pinynhom ebën.
As of March 2, 2020, the virus has resulted in over 80,000 confirmed cases of COVID-19, with more than 40,000 patients discharged and over 3,000 patients who died.
Ku na ye aköl nïïn 2 pɛi Diäk ruon 2020, guɔ tuany rɔt tɛk pinynhom ku ran 80,000 ke cï luaŋ e tuɛny COVID-19, ran 40,000 aacï kek lony bɛ̈ɛ̈i akïm iic, ku ran 3,000 ke cï thou.
WHO warns that COVID-19 is “public enemy number 1” and potentially more powerful than terrorism.
Aci WHO luel lɔn ye COVID-19 "adun nimra 1" ku arac ke wär kɔc nɔ̈k.
According to PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), in less than two months, over 200 papers have been published on COVID-19 including its virology, epidemiology, etiology, diagnosis, and treatment since the first report on January 7, 2020 that determined the sequence of the virus isolated from multiple patients.
Acï Athɔ̈ PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), luel lɔn cï athɔ̈ɔ̈r 200 gät aɣer alɔŋ COVID-19 pɛ̈i karɔu iic alɔŋ käm, te ye käk gɛ̈l thïn, te tuany jɔk thïn, te ye ŋiëc yen ku jɔl a elacde jɔk cɔ̈k raan tueŋ akɔŋ yɔ̈k kela guop tuany pɛi Tök aköl 7, 2020 ye nyuɔth te ye kɔc cï luaŋ mɛc wei kɔc lɔm.
This review attempts to summarize the research progress in the new and swiftly developing subject area.
Athɔ̈r kën awïc ku bï te le tuany tueŋ thïn ku ke looi bï tuany gɛ̈l.
Whenever possible, we will try to compare COVID-19 with SARS and another CoV-caused disease, Middle East respiratory syndrome (MERS, an outbreak in 2012).
Aabuk them ku buk COVID-19 thɔ̈ɔ̈ŋ kek SARS ku cɔl a tuany dɛ̈t ye CoV bɛ̈i, tuɛny pan Arab Middle East (MERS, tauny acï jɔt ruon 2012).
We will also discuss what we have learned so far regarding the prevention and prognosis of the disease as well as some remaining yet urgent questions.
Kë cuk piɔ̈c aabuk jamic aya tecït te ye tuany gɛ̈l thïn ku ke ŋicku alɔŋ tuany ku jɔl aa kïït thiëc ŋɔɔt.
CoVs have been traditionally considered nonlethal pathogens to humans, mainly causing approximately 15% of common colds 4.
Acï yɔ̈k lɔn ce CoV kɔc e nɔ̈k, ku e tecït tën 15% juän 4.
However, in this century, we have encountered highly pathogenic human CoVs twice, i.e., SARS-CoV and MERS-CoV, which caused an outbreak originally in China in 2003 and Saudi Arabia in 2012, respectively, and soon spread to many other countries with horrible morbidity and mortality.
Jildan kën, ok aacï tuɛnytuɛny CoV yɔ̈k arak rɔu ku aa kek SARS-CoV ku MERS-CoV ku e pan China yen ye kek jɔk thïn ruon 2003 ku Saudi Arabia ruon 2012, ku jɔl guɔ tɛk piny bï tuany ku thuou dït
Therefore, the current COVID-19 is the third CoV outbreak in the recorded history of humans.
Ku keya, COVID-19 yaköle e CoV ye kek diäk cï rɔt looi anyikɔ̈l man raan ic.
As shown in Fig. ​Fig.1,1, clusters of pneumonia that had unknown origins were first reported from Wuhan on December 31, 2019 to the China National Health Commission.
Cïmen cï yen nyuɔth thura. Thura. 1,1, tuɛnytuɛny puou aa ke kɔŋ cal gen Wuhan pɛi thiärkurɔu aköl 31, 2019 ten akut kɔc käk pial guop pan China.
Seven days later the sequence of the CoV was released.
Ku nïïn kädhorɔu cɔ̈k ciɛ̈n tuany CoV rɔt jɔt.
On January 15, 2020 the first fatal case from Wuhan was reported.
Aköl nïïn 15 pɛi Tök, ruon 2020, ran tueŋ cï luaŋ gen Wuhan ecï cal.
Meanwhile, the epidemic rapidly spread to the neighboring cities, provinces, and countries.
Ku jɔl thiɛ̈i piny tën gɛɛth, wuöt ku bɛ̈ɛ̈i dït thiäk kek yen.
On January 20, the infection of health-care providers was reported, suggesting that human-to-human transmission was possible.
Aköl nïïn 20 pɛi Tök go cal lɔn cï yen akïm dom, ku jɔl luel lɔn lɛ̈u yen rɔt ku bï randä täu randä guop.
On January 23, the city of Wuhan was locked down with all its public transportation stopped.
Na ye aköl nïïn 23 pɛi Tök, go gen Wuhan thiɔ̈k piny agut käk ye kɔc ke cath.
On January 24 the first clinical study on the disease reported that, out of 41 patients with confirmed cases, only 21 had direct contact with the Wuhan seafood market that was considered the starting site of the infection from an unknown animal source.
Aköl nïïn 24 pɛi Tök kam kɔc ke cï ke them gup, tecït tën ran 41 ke cï luaŋ, ran 21 aacï yɔ̈k ke cï la thuŋ Wuhan Seaford ye tak lɔn ye yen ten jɔk yen rɔt thin lan kuc guopic.
On January 30, WHO declared the outbreak a global health emergency.
Aköl nïïn 30 pɛi Tök, go WHO cal keye tuany piny.
By the time of this report, the disease has already spread throughout China and near 50 other countries all over the world (Fig. ​(Fig.2).2).
Ke athɔ̈rkën kï guɔ bën bei, ka tuany acï ɔt tɛk piny China ic ebën ku tecït tën gɛu 50 pinynhom (Thura. (Thura.2)2).
As the situation is rapidly evolving, the final scope and severity of the outbreak remain to be determined.
Te bï tuɛny ken yiɛ̈n thïn ku te bï dɔ̈ɔ̈t, rɛ̈ɛ̈cde aŋuɔt kïc detic.
On February 11, 2020, a multi-center study on 8,866 patients including 4,021 confirmed COVID-19 patients presented a more updated illustration of the epidemic as follows (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA).
Aköl nïïn 11, pɛi Rɔu ruon 2020, te ye tuany kuen thïn acï tecït tën raan 8,866 agut ran 4,021 cï luaŋ COVID-19 aacï tuany ken nyuɔth ku aye yɔ̈k (https://mp.weixin.qq.com/s/UIBi-HX_rHPXa1qHA2bhdA).
SARS-CoV-2 infected people of all ages, but mainly at the age of 30-65.
SARS-CoV-2 e kuat raan ebën dom, meth, randit, ku kɔc ye lac dom a raan la ruon 30-65.
Almost half (47.7%) of the infected individuals were over 50 years old, very few were under 20, and only 14 infected individuals were under the age of 10.
Kɔc cï luaŋ iic (47.7%) aa kɔc la ruon 50, kɔc thiinyɔt aa kek la ruon 20, e raan 14 aa kek la ruon 10.
SARS-CoV-2 infected more men (0.31/100,000) than women (0.27/100,000).
SARS-CoV-2 acï rɔ̈ɔ̈r juëc dom (0.31/100,000) te thɔ̈ɔ̈ŋ kek diäär (0.27/100,000).
COVID-19 expanded in clusters mainly in and around Hubei.
COVID-19 acï rɔt juak Hubei alɔ̈ŋthïn ku aɣer.
COVID-19 took an average of 5 (2-9) days from onset to diagnosis.
COVID-19 acï nïïn thiinyɔt nɔ̈k mën jɔ̈k yen ku bï jäl ŋic. Nïïn 5 (2-9).
The average incubation period was 4.8 (3.0-7.2) days.
Nïïn ye nɔ̈k ku bï rɔt dhiɛ̈th e 4.8 (3.0-7.2).
The average time from onset to death was 9.5 (4.8-13) days.
Kam ye nɔ̈k ku bï jäl e 9.5 (4.8-13) nïïn.
The basic reproductive number (R0) was 3.77 (95% CI: 3.51-4.05), and the adjusted R0 was 2.23-4.82.
Nimra den dhiɛ̈th (R0) e ye 3.77 (95% CI: 3.51-4.05), ku (R0) cï cɔ̈k piny e ye 2.23-4.82.
The number of infected people increased exponentially before 23 Jan. 2020, matching the time of massive transportation before the Spring Festival in China.
Adat kɔc cï luaŋ agɔ rɔt juak ke aköl nïïn 23 pɛi Tök ruon 2020 kï bën, thɔ̈ɔ̈ŋ kek kam ye kɔc cath ke yan ajɔ̈k ruon pan China kï guɔ bën.
The mortality of patients with confirmed cases was 1.44% (95% CI: 1.10-1.86%), and the adjusted mortality of all the patients was 3.06% (95% CI: 2.02-4.59%).
Adat kɔc cï thou rin tuany e 1.44% (95%CI:1.10-1.86%), ku thuou cï rɔt cɔ̈k piny kɔc tuany e 3.06 (95%CI: 2.02-4.59%).
Three major risk factors for COVID-19 were sex (male), age (≥60), and severe pneumonia.
Käk ye ke rɛ̈ɛ̈c COVID-19 ŋic thïn e kuat (moc), run (60 le tueŋ) ku tuɛny puou cɔl namonia.
CoVs are a subfamily of large and enveloped viruses containing a single strand of sense RNA.
CoV e macthok ku e kuat kämdït e tuɛnytuɛny guop bɛ̈i la ic RNA tök.
They can be divided into four genera, i.e., alpha, beta, gamma, and delta, of which alpha- and beta-CoVs are known to infect humans.
Kek aacï kek tekic ŋuan cïmen alpha, beta gamma ku delta ku e alpha- ku kek beta-CoV aakek kɔc luaŋ.
The envelope spike (S) glycoprotein binds to its cellular receptors angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) for SARS-CoV and MERS-CoV, respectively, and then membrane fusion occurs.
Miöök (S) glycoprotein ku angiotensin rɔ̈t loi bïk ya miök 2 (ACE2) ku 4 (DPP4) käk SARS-CoV ku MERS-CoV, aacï rɔ̈t mat ku jal kä dɛ̈l liäp nhom.
The viral RNA genome is released into the cytoplasm; after replication of the viral genome, genomic RNA accompanied by envelope glycoproteins and nucleocapsid proteins forms virion-containing vesicles, which then fuse with the plasma membrane to release the virus.
Tuany jäl guopic RNA acï jal bï la dɛ̈l ic, ku na wën cï RNA jal liääp kek dɛ̈l , ku ala ic protin cɔl glycoprotein ku nucleoucapsid aacï liääp ku bïï köm cɔl abɔ̈.
The first genomic sequence of SARS-CoV-2 was reported on January 10, 2020.
Jɔ̈k cɔ̈k SARS-CoV-2 e pɛi Tök aköl nïïn 10 ruon 2020.
SARS-CoV-2 was found to be a new type of beta-CoV with more than 99.98% genetic identity among 10 sequenced samples collected from the original site of the outbreak, the Huanan Seafood Market in Wuhan.
SARS-CoV-2 acï yɔ̈k keye kuat-CoV tecït te cï 99.98% ye nyuɔth käŋ kä 10 cï kek looi pan jɔ̈k tuany thïn, thuŋ Huanan Seafood gen Wuhan.
SARS-CoV-2 is genetically more similar to SARS-CoV than to MERS-CoV.
SARS-CoV-2 athɔ̈ɔ̈ŋ kek SARS-CoV tën MERS-CoV.
Through transmission electron microscopy, SARS-CoV-2 particles were found in ultrathin sections of human airway epithelium.
Dhel ye köm rɔt tɛk piny, athueithuei SARS-CoV-2 aacï ke yɔ̈k wɛ̈nh ye kɔc them gup thok te ye ran wɛ̈i thïn.
Human ACE2 was found to be a receptor for SARS-CoV-2 as well as SARS-CoV.
SARS-CoV-2 ku SARS-CoV aa yeke yɔ̈k ACE2 raan ic te ye ran wɛ̈i thïn.
However, the S protein of SARS-CoV-2 binds to human ACE2 more weakly than that of SARS-CoV, which is coincident with the fact that SARS-CoV-2 causes less severe infection in patients than SARS-CoV.
Ku keya, protin S kën SARS-CoV-2 cï rɔt mat kek ACE2 te ye ran wɛ̈i aa liɔ̈ɔ̈i tën SARS-CoV, kën yen nyuɔth lɔn ade ka SARS-CoV-2 acï guop ran tuany ic cïmen SARS-CoV.
SARS-CoV-2 can also form a novel short protein encoded by orf3b and a secreted protein encoded by orf8.
SARS-CoV-2 e miök cɔl acil miök ye cɔl orf3b ku miök cï thian ye cɔl orf8.
The orf3b of SARS-CoV-2 may play a role in the viral pathogenicity and inhibit the expression of IFNβ; however, orf8 does not contain any known functional domain or motif.
Miök orf3b kën SARS-CoV-2 anaŋ keye looi guop ku bï thɔ̈ɔ̈r kek käm guop ku köök keye cɔl IFNB ic; ku keya orf8 acïn keye kony guopic.
On February 18, 2020, Zhou, et al., reported the cryo-EM structure of the full-length human ACE2 at 2.9 Å resolution in complex with the amino acid transporter B0AT1.
Acï Zhou, et al, luel aköl 18 pɛi rou, 2020, ke te ye kɔc wɛ̈i ye cryo-EM kek ACE2 tecït tën 2.9 rɔt liääp kek pïïu wat rɔ̈lic ye cɔl B0AT1.
They found that the complex, which had open and closed conformations, was assembled as a dimer and the ACE2-B0AT1 complex can bind two S proteins, which provides evidence for CoV recognition and infection.
Acï yɔ̈k lɔn na cï ACE2-B0AT1 rɔt mat ke miök puou, ka nyɔth CoV ku bï ŋic ku nyɔth tuany.
B0AT1 may become a therapeutic target for drug screening to suppress SARS-CoV-2 infection.
B0AT1 alɛ̈u bï kɔc kony bï wäl lɛ̈u bï SARS-CoV-2 thany piny yɔ̈k.
The origin and intermediate host
Te ye yen jɔk thïn ku te ye yen rɛ̈ɛ̈r thïn
It has been known that both SARS-CoV and MERS-CoV originated from bats and were transmitted to humans via civet cats and camels, respectively.
Acï ŋic lɔn ade ka SARS-CoV ku jɔl a MERS-CoV abɔ bei alïk gup ku jɔl kä rɔt tɛk kɔc gup e lääi cïmen aŋau ku jɔl a thɔ̈rɔ̈ɔ̈l kedhie.
Through a phylogenetic comparison of SARS-CoV-2 with other CoVs, bats were considered the native host of SARS-CoV-2 as the new virus is 96% identical to two SARS-like CoVs from bats called bat-SL-CoVZX45 and bat-SL-CoVZX21.
Thɔ̈ɔ̈ŋ cï käk guop thɔ̈ɔ̈ŋ kek SARS-CoV-2 kek Covs, aliɛ̈k aacï ke yɔ̈k ke la gup SARS-CoV-2 rin tecït tën 96% SARS athɔ̈ɔ̈ŋ kek CoVs ku aye yɔ̈k tën alïŋ ye cɔl SL-CoVZX45 ku alïŋ ye cɔl SL-CoVZX21
However, what intermediate host helped the virus cross the species barrier to infect humans remains unknown, and the transmission route is yet to be elucidated.
Kën cɔl adɔm ran acï ŋic gut emën, ku ye yen la ran guop thïn aŋuɔt yop.
Ji, et al., proposed snakes as a carrier of the virus from bats to humans which involved homologous recombination within the S protein.
Acï Ji, et al luel lɔn ye yen yɔ̈k kupiɛny gup rin yen cam aliɛ̈k ku ela ran tecï miök ye ran wïc liääp.
According to a study, researchers in Guangzhou, China, suggested that pangolins - long-snouted, ant-eating mammals often used in traditional Chinese medicine - are the potential intermediate host of SARS-CoV-2 based on 99% genetic homology in a CoV discovered in pangolins and SARS-CoV-2.
Acï kɔc ce yop pan Guangzhou, China luel kala lääi ye cɔl pangolin - e cam dhiëi ku aye täu wɛl piny ic aa dhil kek SARS-CoV-2 ɣäc tecït tën 99% guopic tecït te cï yɔ̈k yen CoV pangolin gup ku jɔl a SARS-CoV-2.
However, 1% difference spread all over two genomes is still a big difference; thus, conclusive results for concrete evidence are awaited (Fig. ​(Fig.33).
Ku keya, 1% dɔ̈ŋ kën e rɔt tɛk piny ku ken tuany kën bɛ̈i aŋuɔt ŋot (Thura (thura 33).
The physicochemical properties of SARS-CoV-2 are largely not yet known.
Käk tuany SARS-CoV-2 bɛ̈i aŋuɔt ke kuc yemën.
SARS-CoV and MERS-CoV can survive in vitro for 48 hours in a dry environment and up to 5 days under 20 °C and 40%-50% humidity.
Käm cɔl SARS-CoV ku MERS-CoV aa pïïr tecït ten thau 48 tecïn ic pïïu ku aa pïïr tecït tën nïïn kä 5 te liir 20*C ku jɔl a 40%-50% aliɛr ic.
SARS-CoV-2 may possess similar properties.
SARS-CoV-2 ala kä tɔ̈ɔ̈ŋkä.
It has been reported that SARS-CoV-2 is sensitive to ultraviolet rays and heat at 56 °C for 30 minutes; ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, chloroform, and other fatty solvents, but not chlorhexidine, can effectively inactivate the virus.
Acï luel lɔn SARS-CoV-2 a rilic ku bï lac tïŋ wɛth ku e tuöc degree 56 tecït tën yuul 30, ether, 75% ethanol, chlorine - la ic wal ye käm nɔ̈k, peracetic acid, chloroform, ku kuat käk la iic miök, ku wal ye cɔl chlorhexidine e köm nɔ̈k.
The entire human population generally lacks immunity to SARS-CoV-2 and hence is susceptible to the novel virus.
Kɔc aacïn gup riɛl bï kek SARS-CoV-2 tiɛt wei ku e yen cï köm cɔl adït.
Currently, no detailed study has been reported regarding the immunological response to SARS-CoV-2.
Yemën thiin, acïn ke cï gɔ̈t ke ye të bï SARS-CoV-2 ya tɔm thïn.
Thus, we can only refer to previous studies on other CoVs, especially SARS-CoV and MERS-CoV (Fig. ​(Fig.4).4).
Ku keya, alɛ̈u ku buk ke cï gɔ̈t thɛɛr ya buɔthic alɔŋ CoV, cïmen SARS-CoV ku MERS-CoV (Thura. (thura.4).4).
In general, after a virus invades the host, it is first recognized by the host innate immune system through pattern recognition receptors (PRRs) including C-type lectin-like receptors, Toll-like receptor (TLR), NOD-like receptor (NLR), and RIG-I-like receptor (RLR).
Te ŋïc yen, te cï köm la guopic, ku dɔm anyanya thɔ̈ɔ̈r kek käm ku le (PPRs) gam keye abaŋ C, ku abaŋ (TLR), alɔŋ NOD cïmen (NLR) ku IG-I keye abaŋ (RLR).
Through different pathways, the virus induces the expression of inflammatory factors, maturation of dendritic cells, and synthesis of type I interferons (IFNs) which limit the spreading of the virus and accelerate macrophage phagocytosis of viral antigens.
Dhɔ̈ll juëc, köm e rɔt looi bï naŋ kën kɔc cuɔ̈ny, ku e cil dɛ̈l kɔ̈u, ku e rɔt mat kek abaŋ dɛ̈l ye cɔl (IFNs) kën köm gɛ̈l ku bï rɔt cï tet piny ku thɔ̈ɔ̈c riɛm thɔ̈ɔ̈r kek käm.
However, the N protein of SARS-CoV can help the virus escape from the immune responses.
Ku keya, kuat miök N e tuanyy cɔl SARS-CoV e köm kony ku bï anyanya guop cï näk.
Soon, the adaptive immune response joins the fight against the virus.
Ku etën, anyanya thɔ̈ɔ̈r guopic aa rɔt mat ku bïk thɔ̈ɔ̈r kek köm.
T lymphocytes including CD4+ and CD8+ T cells play an important role in the defense.
Kuat anyanya thɔ̈ɔ̈r guopic T la ic CD4+ ku CD8+ T aala keye kä yekä looi tiɛ̈tic guöp.
CD4+ T cells stimulate B cells to produce virus-specific antibodies, and CD8+ T cells directly kill virus-infected cells.
Anyanya thɔ̈ɔ̈r guopic CD4+ T tɔ̈u riɛm B ic e anyanya tɔc ku bïk gɛ̈l, ku anyanya thɔ̈ɔ̈r guopic CD8+ T aa köm nɔ̈k nyinic.
T helper cells produce proinflammatory cytokines to help the defending cells.
Anyanya thɔ̈ɔ̈r guopic abaŋ T aa mac tuöc ku naŋ ke kony anyanya riɛm.
However, CoV can inhibit T cell functions by inducing apoptosis of T cells.
Keya, CoV ala anyanya riɛm abaŋ T ku näk kä anyanya riɛm la iic köm.
The humoral immunity including complements such as C3a and C5a and antibodies is also essential in combating the viral infection.
Käk thɔ̈ɔ̈r riɛmic cïmen C3a ku C5a apath alɔŋ näk köm ke la iic anyanya thɔ̈ɔ̈r guopic.
For example, antibodies isolated from a recovered patient neutralized MERS-CoV.
Käk riɛm thɔ̈ɔ̈r cï ke thok lel tën raan cï ŋuɛ̈n a tuany cɔl MERS-CoV muör nyin.
On the other hand, an overreaction of the immune system generates a large number of free radicals locally that can cause severe damages to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.
Te cï anyanya riɛm nhïïm ku jɔl kuat kën la guopic nyai ka lɛ̈u bï cuɛ̈ny ku ka yiic kök rac ku alɛ̈u ku bï thuou bɛ̈i.
The SARS-CoV-2 infection, featured by clustering onset, is more likely to affect elderly people with comorbidities and pregnant women.
Wuɔk de SARS-CoV-2, ë ye nyuɔth në wëŋë thok ë jɔ̈k, la ic akut tuɛnytuɛny kɔ̈k aa kɔc cï dït luɔ̈i ku jɔla diäär liɛc guɔ dom.
It is common that for people who are exposed to a large number of viruses or whose immune functions are compromised, they have higher chance to be infected than others.
E kën rot lac looi lɔn ka kɔc la gup käm kök wula riɛmden aliɔi, apuɔl ic tën kek ku bïk guɔ tuany.
The estimated mean incubation period of SARS-CoV-2 is 1-14 days, mostly 3-7 days based on a study of the first 425 cases in Wuhan.
Nïïn ye SARS-CoV-2 dhiɛ̈th e 1-14, ku e tecït tën nïïn kä 3-7 tecït te cï yen yɔ̈k thïn ten ran 425 ci luaŋ gen Wuhan.
However, a study on 1,099 cases demonstrates that the incubation period was 3 days on average and ranged from 0 to 24 days.
Aye kɔc ce kuen alɔŋ ran 1,099 kɔc cï luaŋ nyuɔth lɔn ye ye dhiɛ̈th e nïïn ka 3 iic ku etɔ̈u kam pinyic 0 le nïïn 24.
A more recent study, as described above, demonstrates that the incubation period was 4.8 (3.0-7.2) days based on the demography of 8,866 cases.
Ke cï yɔ̈k kɔc ce kuenic cïmen cï yen luel tueŋ tetui, kam ye nɔ̈k ku bï dhiɛ̈th e 4.8 (3.0-72) tecït ten adat raan 8,866 cï luaŋ.
It is very important for health authorities to adjust the effective quarantine time based on the most accurate incubation period, thus preventing infected but symptomless people from transmitting the virus to others.
Akïïm aalɛ̈u ku bïk nïïn ye kɔc tek thok ya caath ku ben ka; ke nhïïm luɔ̈i tecït le tuany tueŋ thïn ku gɛ̈l tuany bï rɔt cï tek piny ten kɔc kök.
As a common practice, individuals exposed to, or infected by, the virus are usually required to be quarantined for 14 days.
Kɔc cï yɔ̈k ke cï luaŋ e tuany aaye kek täu teden ke pɛ̈c nïïn 14.
Should the quarantine time be extended to 24 days?
Lɛ̈u bï nïïn ye kɔc lel thook juak bï ya nïïn 24?
Fever is often the major and initial symptom of COVID-19, which can be accompanied by no symptom or other symptoms such as dry cough, shortness of breath, muscle ache, dizziness, headache, sore throat, rhinorrhea, chest pain, diarrhea, nausea, and vomiting.
Juäi/atuöc yen ye lac nyuɔth lɔn raan COVID-19, ku acïn kïn tuany dɛ̈t lɛ̈u be buɔth cɔk wula kïït kök aalɛ̈u bïk ya cïmen ɣɔl la kök, riɛlic wɛ̈i, te ye rïŋ rem ic, te ye yïn guop la luany, aɣar nhom, ayiɛl rɔ̈l, te ye yï cuɔ̈k wum, arɛm puou, yäc, akɔrpuou, ku aŋɔ̈ɔ̈k.
Some patients experienced dyspnea and/or hypoxemia one week after the onset of the disease.
Kɔc tuany kök aaye wɛ̈i ic riɛl ten kek ku/wula te ce aliir wɛ̈i ben la guop ic tecï raan tuany wudhbuɔ cɔ̈k ciɛ̈n.
In severe cases, patients quickly progressed to develop acute respiratory syndrome, septic shock, metabolic acidosis, and coagulopathy.
Ku na cï tuany ic riɛl, ka atuöc ku arɛm puou aa tuɔ̈l, aliir ace ben la puou ic, miök guop ace ben lui apath, ku jal riɛm kɔl guop ic.